SCHEMBL4664277

SCHEMBL4664277

COc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc(OCC5CCN(C)CC5)c(OC)c4)ncn3)cc2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 14/20 0.43
KDR P35968 4/20 0.40
MET P08581 3/20 0.40
KIT P10721 2/20 0.38
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
FGFR1 P11362 2/20 0.37
FLT1 P17948 2/20 0.37
FLT4 P35916 2/20 0.37
IKBKE Q14164 1/20 0.37
TBK1 Q9UHD2 1/20 0.37
BMPR1B O00238 1/20 0.37
PLK4 O00444 1/20 0.37
CIT O14578 1/20 0.37
GAK O14976 1/20 0.37
EPHB6 O15197 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665748 0.97 EGFR (0.42) EGFRKDRMETKITFGFR1
SCHEMBL4666156 0.95 EGFR (0.41) EGFRKDRMETKITFGFR1
SCHEMBL4663941 0.93 EGFR (0.40) EGFRKDRMEN1USP2ALDH1A1
SCHEMBL4665766 0.92 EGFR (0.44) EGFRMEN1USP2ALDH1A1GAA
SCHEMBL4665796 0.92 EGFR (0.44) EGFRKDRMEN1USP2ALDH1A1
SCHEMBL4665873 0.91 EGFR (0.44) EGFRKDRKITABL1BCR
SCHEMBL4667471 0.91 EGFR (0.44) EGFRKDRMETKITFGFR1
SCHEMBL4665787 0.91 ABL1 (0.41) EGFRKDRMETABL1BCR
SCHEMBL4665886 0.90 EGFR (0.37) EGFRKDRMEN1USP2ALDH1A1
SCHEMBL4665630 0.90 PIK3R1 (0.45) EGFRKDRMETKITMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885KDR 431/4885MET 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.